Skip to content

Measuring Cognitive Enhancement During Hyperbaric Oxygen Treatments

Measuring Cognitive Enhancement During Hyperbaric Oxygen Treatments

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04358796
Enrollment
69
Registered
2020-04-24
Start date
2017-11-10
Completion date
2018-11-02
Last updated
2020-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperbaric Oxygen Therapy

Keywords

Cognitive enhancement, Memory, Information processing speed, Hyperbaric oxygen treatments

Brief summary

The aim of the current study was to examine the effect of short-term HBOT (hyperbaric oxygen treatments) on a range of cognitive abilities. The current study examined whether there is a HBOT-related short-term cognitive improvement and, if so, what specific cognitive abilities are improved by the intervention. Participants were randomized to perform cognitive tasks in one of two chambers with two different clinical environments: (a) HBOT condition: (2 ATA (atmosphere absolute) 100% oxygen for 90 minutes). (b) Control condition: in which the chamber was not pressurized (Normobaric condition- 1 ATA for 90 minutes).

Detailed description

The aim of the current study was to examine the effect of short-term HBOT on a range of cognitive abilities. The current study examined whether there is a HBOT-related short-term cognitive improvement and, if so, what specific cognitive abilities are improved by the intervention. Participants were recruited through ads on the internet and on student social groups. All participants underwent a comprehensive physical and neurological examination, and general medical conditions were ruled out. Participants were excluded if reported changes in their cognitive or behavioral functions during one month prior to the beginning of the study. Smokers (people who smoke more than seven cigarettes a week) were required to take a lung x-ray confirming there isn't a pulmonary pathology, such as pneumothorax, pulmonary bullae, emphysema, or other lung pathologies preventing them from staying in a high ATA environment. Participants with an abnormal x-ray were excluded from the study. Participants who regularly use Methylphenidate (i.e. Ritalin) or other stimulants for attention disorders (i.e. ADHD) were instructed not to take it at the day of the experiment. Following consent, all the participants were exposed to the testing battery in a group setting. One of the experimenters went through each of the sub-tests instructions in a detailed manner prior to a practice phase in which participants trained on the tasks. Afterwards, participants were randomized to perform the tasks in one of two chambers with two different clinical environments: (a) HBOT condition: (2 ATA 100% oxygen for 90 minutes). The atmospheric pressure in this condition was set to 2 ATA. This ATA level is known to have a clinical effect, whereas higher-pressure levels may result in inhibitory brain effects or even lead to focal toxicity (Efrati and Ben-Jacob, 2014). (b) Control condition: in which the chamber was not pressurized (Normobaric condition- 1 ATA for 90 minutes) and participants breathed air (21% oxygen). In this condition, ATA was elevated for a few minutes to 1.2 ATA in order to mimic the feeling of pressure building up in the ears. The pressure was decreased soon after to 1 ATA. The assessment began 30 min after participants wore the oxygen masks within the chamber, in order to enable appropriate brain oxygenation in the HBOT condition (Vadas et al., 2017). The battery was composed of cognitive tests adapted for high functioning subjects and adjusted to an in-chamber group administration setting.

Interventions

DEVICEHyperbaric oxygent treatment

Subjects will enter the oxygen chamber. ATA will be elevated to 2 ATA. They will breath 100% oxygen while solving cognitive tests designed to assess their cognitive capacities

DEVICEControl hyperbaric oxygen treatment

Subjects will enter the oxygen chamber. ATA will be elevated to 1.2 ATA for a short while and the decreased back to 1 ATA. They will breath air while solving cognitive tests designed to assess their cognitive capacities

Sponsors

Assaf-Harofeh Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Patients are unaware to the ATA in chamber and to oxygen levels in their mask.

Intervention model description

two groups being tested in parallel. The first group in HBOT environment. The second group in a SHAM environment.

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 20-40 * intact sight / corrected sight * Hebrew as mother tongue * Intact comprehension

Exclusion criteria

* Active neurologic or psychiatric diagnosis. * If Had been treated with HBOT for any other reason prior to their inclusion; * Chest pathology ; * Inner ear disease; * Claustrophobia;

Design outcomes

Primary

MeasureTime frameDescription
memoryafter 20 minutes of interventionNumber of words retrieved from a list
Working memoryafter 20 minutes of interventionaccuracy rates on a working memory paradigm (n-back)
Divided attentionafter 20 minutes of interventionaccuracy rates on a divided attention task (identifying visual and auditory targets)
Information processing speedafter 20 minutes of interventionAccuracy rates on an information processing speed task (Symbol tracing task)
Response inhibitionafter 20 minutes of interventionAccuracy rates on a response inhibition task (stroop)
Problem solvingafter 20 minutes of interventionaccuracy rates on a problem solving task (solving arithmetic series)

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026